SEER - seer.bio Operating income before deduction of amortization

Graphic logo of seer.bio (SEER)

The current EBITDA level of Seer, Inc. (SEER) reflects a trend supported by production automation and the robotization of client laboratories. The value 0.00 represents the latest metric reading, driven by the expansion of the protein analyzer base and IT contracts with genomic behemoths. Business stability is further complemented by a standard approach to ecology through the safe disposal of electronics and office energy efficiency.

SEER Seer Bio Operating profit before deduction of amortization (11/23/2025 - 11/10/2026)

Seer (SEER) - metric breakdowns and financial figures

- current price and projected stock value:
Price Seer Bio|SEER - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Seer|SEER - Enterprise Value
- balance sheet equity data:
Accounting Value per Share Seer|SEER - Company Net Assets|Market Value to Book Value seer.bio|SEER - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Seer, Inc.|SEER - Long-Term Debt to Capital|Current Liabilities to Capital Seer Inc|SEER - Company Aggregate Debts|Debt to Book Value Ratio Seer|SEER - Company Long-Term Debts|Short-Term Debt Volume Seer|Quick Liquidity Indicator seer.bio
- earnings and multiples data:
SEER - Net Profit|Projected Future Earnings Seer, Inc.|SEER - Price to Earnings Ratio|Future Price to Earnings seer.bio|SEER - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Seer|SEER - Operating profit EBITDA|Net earnings per one share for the last twelve months Seer|SEER - Earnings per share for the last twelve months|Net earnings per share growth for the trailing year seer.bio|SEER - Net earnings per share growth this year|Earnings growth forecast for next year Seer, Inc.
Summary company analytics:Seer Bio - SEER
Mass-produced product of Seer, Inc.

Fundamental asset screening requires separating market noise from a business's actual cash generation. By analyzing the current EBITDA, an investor can see the net cash flow from operating activities before taxes and depreciation, which confirms the effective commercialization of the Proteograph platform and the strategic resource allocation by Seer, Inc. (SEER) management to ensure long-term scaling.

Who Seer, Inc. competes with

Company profit before taxes, interest and amortization ABT (Abbott Corp.)|Thermo Fisher Scientific - Operating profit EBITDA|Operating income before deduction of amortization gehealthcare.com GEHC|MTD: Operating profit EBITDA|Operating profit before deduction of amortization Waters Corp|Operating profit before deduction of amortization TECH|BRKR: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Azenta, Inc. (AZTA)|Operating profit before deduction of amortization vareximaging.com VREX|Operating profit EBITDA SMLR (Semler Scientific)|Butterfly Network Inc (BFLY) - Profit before interest, taxes and amortization|Mesa Labs Corp - Operating profit EBITDA|QSI (Quantum-Si Corporation) - Operating profit before amortization|NNOX: Operating profit EBITDA|QTRX - Operating income before deduction of amortization|MASS (908 Devices) - Operating profit EBITDA|Operating profit before deduction of amortization CapsoVision Medical (CV)|Operating profit EBITDA MXCT|Operating profit EBITDA rapidmicrobio.com (RPID)|Profit before payment of interest, taxes and amortization Hyperfine, Inc. HYPR|fonar.com - Profit before payment of interest, taxes and amortization|DXR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization MDAI (spectral-ai.com)|VIVS: Operating profit EBITDA|Profit before interest, taxes and amortization Aclarion Corporation (ACON)|Profit before payment of interest, taxes and amortization Akoya Biosciences Inc|THMO - Operating profit before depreciation charges|Operating profit before deduction of amortization TLIS (Talis Biomedical)|Operating profit EBITDA T2 Biosystems Inc. (TTOO)